Connect with us

Breaking

Bitcoin, Ethereum prices under heavy pressure

Published

on

(FinancialPress) — Prices for the main cryptocurrencies are under pressure once more, as BTC prices sink towards $7,400.

The momentum enjoyed by bitcoin at the end of 2017 is nowhere to be found heading into Q2 2018. Despite finding certain stability in prices, the bear tendency is still prevalent. This could see the cryptocurrency drop even lower once more, reaching a bottom as low as $7,400. Bulls have not responded to the positive consolidation and ranging in crypto prices, thus increasing the risk of leaning towards the downside again.

Under Pressure

Even with the current sense of stability, prices have not neared the $8,000 benchmark yet. This could make the trend lean towards the downside, which would make the next price target for bears $7,400. Adding to the pressure, tax season is closing in some of the biggest markets for cryptocurrency. With regulators having laid eyes on the market for the first time, and pushing for declarations of profit and taxes, uncertainty and confusion are to be expected. Both factors will certainly add to the pressure that prices are experiencing.

Ethereum has had a rough ride lately as well. Its prices have dropped in unison with the rest of the digital currency market‘s. Adding to that, uncertainty over the direction in which the ETH network is headed is another notable pressure factor for its prices.

There are no immediate factors of risk that could affect crypto prices in immediate sight, but expect the market to remain under heavy pressure from all angles as we head to the end of Q1 this month.

Ruben is a South American writer who focuses on the state of the cryptocurrency, cannabis and tech industries worldwide.

Breaking

Quanta’s Polarized CBD: Where Plants Meet Quantum Physics

Published

on

CBD, the short name for cannabidiol, remains a hot topic today in the consumer and investment spaces.  Companies are packing the component of hemp and cannabis touted for its powerful positive benefits into a litany of products, ranging from creams to gummies to medicines to food and beverages and everywhere in between.  Why?  Because consumer demand is soaring and the recent passage of the Farm Bill made hemp-derived CBD completely legal, opening up interstate commerce without fears of prosecution.

CBD, which doesn’t contain any of the psychoactive components that result in the “high” frequently associated with cannabis, has a therapeutic index that goes from alleviating symptoms of hard-to-treat diseases like epilepsy to anti-aging skin properties.

This segment of the so-called “green rush” – used to describe cannabis reform sweeping the planet – could be growing faster than the legal marijuana market.  Owing to increased consumer awareness about CBD’s uses and safety profile and relaxed hemp regulations, industry analysts at the Brightfield Group forecast that the hemp-derived CBD market could swell to $22 billion by 2022 from about $580 million in 2018.

At Quanta, Inc. (OTC: QNTA), scientists are using quantum physics to manipulate and stabilize electron spin in naturally occurring elements, including CBD, to increase performance in the body.  The result is CBD that is “polarized,” which brings with it a bevy of benefits that essentially amplify the properties of CBD in a consistent and repeatable fashion.  This means products using polarized CBD are faster acting with stronger healing power that last longer without making a person tired compared to competitor’s products.

Many companies tout increased “bioavailability,” meaning that the active ingredient in their product reaches its target in a more efficient way.  Others have trumpeted innovation in increasing bioenergy (or bio-activity), increasing the physical energy and effectiveness of any percentage of CBD available. 

Burbank, California-based Quanta takes it a step further, saying that its technology is the first to “increase and sustain” bio-activity in CBD.  The applied science company’s flagship product is a muscle rub, a combination of 13 natural ingredients, including, but not limited to, CBD, arnica, turmeric, ginger and sunflower oil.  Aptly branded as “Quanta CBD Muscle Rub,” the proprietary blend of the ingredients maximizes anti-inflammatory relief and circulation while easing aches and pains in muscles and joints for comfort and overall well-being.

Quanta also sells an ultra-premium CBD vape cartridge containing hemp-derived CBD.

According to Quanta, sales of the premium organic rub are improving dramatically since the initial launch just over five months ago.  The company sells the balm through its ecommerce channels in addition to being available in more than 300 doctor’s offices, 100 pharmacies and over 150 retail shops.

Quanta CEO Eric Rice didn’t provide specifics, but did say earlier this month that the muscle rub has built a loyal customer base that has helped bolster sales 70% month-over-month since launch.

Rice added that they are working on adding more distribution partners, including ongoing discussions with several national fitness centers, hospital networks and pain management centers.  The company is also planning to add more products to the portfolio using its polarization technology, for which it will manufacture its own line of CBD products in-house.  The company made the shift in business model from licensing CBD brands to the more lucrative model of manufacturing its own products subsequent to the passing of the Farm Bill.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

MassRoots Expands Product Portfolio with New Partner and Acquisition of COWA Science

Published

on

With predictions that the legal cannabis market will experience non-linear growth in the coming years underscored by ongoing legalization of marijuana worldwide, companies big and small are hustling to build their footprints to capture share in a market that  Grand View Research forecasts will reach $146.4 billion by the end of 2025 (from $7.1 billion in 2016).  Whether companies are touching the once-taboo plant or operating in an ancillary segment, there is no shortfall of growth opportunities as part of an abolishment of eight decades of cannabis prohibition.

For its part, MassRoots (OTCQB: MSRT), a technology and rewards platform at its core, is branching out into different verticals.  Since the start of 2019, the company has penned two substantive agreements that have expanded MassRoots’ portfolio of products and services.

In mid-January, the Los Angeles-based company partnered with We are Kured, a subsidiary of New Age Brands (CSE: NF)(OTC:NWGFF), to serve as the leading online retailer of We are Kured’s best-selling CBD Pen.   The handheld vaporizer pen dispenses cannabidiol, or CBD, a THC-free constituent of hemp and cannabis trumpeted for its therapeutic benefits relating to alleviating inflammation, pain, anxiety, seizures and a host of other symptoms from a variety of maladies without unpleasant side effects or psychotropic buzz often associated with marijuana. 

The pen represents a new revenue stream for MassRoots as the first CBD product to be sold directly through the company’s online platform and social media pages.  MassRoots has more than one million social media followers, in excess of 750,000 email subscribers and hundreds of thousands of unique monthly visitors on its website and application to whom it can market the product.

This month, MassRoots entered a definitive agreement to acquire supply-chain as a service company COWA Science Corp. in an all-stock deal valued at approximately $5.78 million.  The buyout terms are dependent upon COWA Science meeting annual revenue milestones of $2.5 million and $7.5 million, as well as other customary closing conditions.  In short, the terms specify that COWA shareholders are entitled to additional shares if the sales milestones are hit within three years of the effectiveness of the merger.

For 2018, unaudited financials show COWA Science generated revenue of approximately $1.5 million by providing a variety of products and services to its list of about 50 cannabis- and hemp-focused clients.  Upon completion of the transaction, COWA will become a wholly-owned subsidiary of MassRoots.

MassRoots expects the acquisition to be immediately accretive while diversifying its business.  Management expects to build upon the existing COWA Science business to offer a complete cannabis-centric suite covering the full supply chain, including advertising, consumer packaging, process and product development, growing supplements and nutrients, HVAC and more.  On the whole, the new, bigger MassRoots intends to provide a broad mix of offerings to hundreds of licensed cannabis business in key markets across the country.

“Going forward, MassRoots is confident that the addition of COWA Science will increase overall revenues and expand our market presence, with the goal of generating positive cash-flows from operations,” commented MassRoots CEO Isaac Dietrich in the press release on the acquisition.  Dietrich added that the decision to bring COWA Science under his company’s umbrella came after several years of following their business and growth trajectory.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Breaking

After a Solid 2018, BioSig Looks to Continue Success in 2019

Published

on

2018 may have been a tough year for the markets, but it certainly wasn’t for BioSig Technologies (NASDAQ: BSGM), as the little company grew up in a big way.  The fundamental advancements were rewarded by stockholders, evidenced by the shares of BSGM appreciating by 21.3% in 2018. 

Shareholders had plenty of cause to applaud BioSig for a litany of accomplishments.  For starters, the medical device maker graduated from the over the counter markets to a senior exchange, listing on the Nasdaq Capital Market in September.  Further, BioSig raised $13.5 million in quality capital to fund the next steps in expanding the pipeline and commercializing its PURE EP™ System.  The company now has almost 3,400 shareholders.

PURE EP System is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision-making during procedures to diagnose and treat patients with abnormal heart rates and rhythms, including Atrial Fibrillation and Ventricular Tachycardia. In September, the FDA granted 510(k) clearance to BioSig for PURE EP, effectively giving the green light for commercialization of the cutting-edge system.

Some of the finest cardiac medical centers in the world are involved with PURE EP System, namely Mayo Clinic and Texas Cardiac Arrhythmia Institute.  These venerable institutions have signed agreements with BioSig for the first commercial installations of the systems.  17 pre-clinical studies of PURE EP System included other upper echelon institutions, such as Mount Sinai and UCLA medical centers.

All of this research and preparation laid the groundwork for BioSig to conduct the First-in-Human study of PURE EP System, which is expected this quarter and will be hosted by Mayo Clinic and Texas Cardiac Arrhythmia Institute.  This is a critical component of commercialization, with other leading centers expected to install the system and provide feedback subsequent to the human study.  This information is part of a methodical approach that will allow BioSig to be properly positioned to ramp-up commercialization efforts in 2020.

To that point, results from the human trial is planned to be presented in May at Heart Rhythm Scientific Sessions, the largest event in BioSig’s industry, where the company can show-off its technology to a large community of potential customers.

Looking further down the road, Mayo Clinic has come on as a strategic collaborator to explore other indications and applications where PURE EP System could prove valuable in treating patients with different diseases and conditions.

BioSig also expanded its global footprint as it looks ahead to commercialization of PURE EP System and future innovation.  New hubs were opened in Austin, Texas and Norwalk, Connecticut, joining the corporate headquarters in Santa Monica, California and rep office in Geneva, Switzerland.

Internally, the company is stronger than ever with the formation of an Advisory Board made up of seasoned veterans lending their expertise in finance, commercialization, government affairs, capital markets, clinical fields and strategic partners.

Backstopped by these developments and upcoming milestones, ROTH Capital Partners has given BSGM a “Buy” rating with a price target of $14.00 per share.  After closing December 31, 2018 at $4.27, shares are up 19.9% so far in 2019 as of the close of trading on Friday, February 15, 2019, meaning ROTH sees a lot more upside to BioSig as commercialization of PURE EP System draws closer.

Online Media Group, Inc. is not registered with any financial or securities regulatory authority and holds no investment licenses and does not provide, nor claims to provide, investment advice. We are a publisher of original and third-party news and information. This article is sponsored content and is neither an offer nor recommendation to buy, sell or hold any security. The views expressed are our own and not intended to be the basis for any investment decision. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader’s attention to the fact that Online Media Group, Inc. received $1,333 in compensation from a third-party for content creation, advertising and distribution services related to this material.

Continue Reading

Most Popular